3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Glioblastoma
21
Brain Neoplasms
15
Central Nervous System Neoplasms
14
Astrocytoma
9
Glioma
7
Oligodendroglioma
5
Medulloblastoma
4
Neoplasms
3
Lymphoma
3
Gliosarcoma
3
Recurrence
2
Melanoma
2
Lymphoma, AIDS-Related
2
Leukemia, Myeloid, Acute
2
Uveal Melanoma
1
Spinal Cord Neoplasms
1
Solid Tumor
1
Optic Nerve Glioma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors
1
Lung Neoplasms
1
Intraocular Lymphoma
1
Familial ependymoma
1
Ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Cognition Disorders
1
Carcinoma, Non-Small-Cell Lung
1
Camurati-Engelmann Syndrome
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
senaparib
7
pembrolizumab
7
Irinotecan
6
Paclitaxel
5
Docetaxel
5
Cisplatin
5
Capecitabine
5
Nivolumab
4
Fluorouracil
4
Bevacizumab
4
Rifampin
3
Midazolam
3
Leucovorin
3
Itraconazole
3
Injections
3
pertuzumab
2
ontuxizumab
2
navoximod
2
atezolizumab
2
Gemcitabine
2
vofatamab
1
tremelimumab
1
trastuzumab duocarmazine
1
talazoparib
1
sotorasib
1
sintilimab
1
saracatinib
1
rucaparib
1
ridaforolimus
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Solid Tumor
×
Lomustine
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled